drugset / Trial / NCT05118724
Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin
Phase 2
Active not recruiting
80 enrolled
AIO-Studien-gGmbH
Immodulon Therapeutics Ltd · collabRoche Pharma AG · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
The investigators hypothesize that atezolizumab will improve the prognosis of patients with stage III dMMR CRC ineligible for or refusing oxaliplatin-based adjuvant chemotherapy compared to SOC and that these could therefore be promising therapeutic options.
Timeline
- Start
- 2021-12-10
- Primary completion
- 2027-04
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 840 mg | Intravenous |
| Subject | IMM-101 | Other / unclassified | 1 mg | Other |